Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL847735 | 0.89 | TAS1R3 (0.38) | CA1CA2CA9RECQL | |
| SCHEMBL16932538 | 0.88 | CA1 (0.33) | CA1CA2CA9RECQLHSD17B10 | |
| SCHEMBL16982882 | 0.87 | TAS1R3 (0.37) | CA1CA2CA9 | |
| SCHEMBL1401584 | 0.86 | RECQL (0.39) | CA1CA2CA9RECQLHSD17B10 | |
| SCHEMBL17065139 | 0.84 | CES2 (0.34) | — | |
| SCHEMBL516304 | 0.81 | CA1 (0.36) | CA1CA2CA9RECQLHSD17B10 | |
| SCHEMBL10710114 | 0.80 | KMT2A (0.46) | HSD17B10SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1401602 | 0.80 | MAPT (0.43) | CA1CA2HSD17B10HTTSMN1; SMN2 | |
| SCHEMBL18480975 | 0.80 | RECQL (0.33) | RECQLHTT | |
| SCHEMBL5533582 | 0.80 | TSHR (0.39) | CA1CA2CA9HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122025825-A | Electrolyte, battery and electricity utilization device | 广州汽车集团股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4619038-A2 | ANIONICALLY FUNCTIONALIZED POLYPEPTIDES, AND METHODS OF MAKING SAME AND USES THEREOF | Cornell University (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-06-26 | — | — | US | claimed |
| WO-2025103475-A1 | HETEROCYCLIC CARBONYL DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-05-22 | — | — | WO | claimed |
| US-20250167304-A1 | LITHIUM ION BATTERY | SVOLT ENERGY TECHNOLOGY CO., LTD. (CN) | 2025-05-22 | — | — | US | claimed |
| CN-115064762-B | Lithium ion battery | 蜂巢能源科技股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119674227-A | Quick-charging electrolyte, lithium ion battery, and preparation method and application of quick-charging electrolyte and lithium ion battery | 中国科学院大连化学物理研究所 | 2025-03-21 | — | — | CN | claimed |
| CN-119361834-A | Electrolyte and battery and electricity utilization device containing same | 浙江大学 | 2025-01-24 | — | — | CN | claimed |
| EP-4465401-A1 | LITHIUM ION BATTERY | SVOLT Energy Technology Co., Ltd. (CN) | 2024-11-20 | — | — | EP | claimed |
| CN-118367217-A | High-voltage-resistant electrolyte and application thereof in high-power graphite-sodium-antimony-based double-ion battery | 温州大学碳中和技术创新研究院 | 2024-07-19 | — | — | CN | claimed |
| EP-0888543-A4 | AZATIDE PEPTIDOMIMETICS | SCRIPPS RESEARCH INST (US) | 2004-04-07 | — | — | EP | claimed |
| US-6664372-B1 | Solution phase synthesis on a soluble homopolymer support by reacting tert-butoxycarbonyl-protected aza-amino acids with bis(pentafluorophenyl) carbonate as carbonyl activation element and coupling to support; combinatorial chemistry | THE SCRIPPS RESEARCH INSTITUTE | 2003-12-16 | — | — | US | claimed |
| EP-1159282-A4 | COMPOUNDS, PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MIXED BACKBONE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2002-08-28 | — | — | EP | claimed |
| EP-1159282-A1 | COMPOUNDS, PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MIXED BACKBONE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | claimed |
| US-20010016652-A1 | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2001-08-23 | — | — | US | claimed |
| US-6207819-B1 | SYNTHESIZING OLIGONUCLEOTIDE BY DEBLOCKING AND COUPLING NUCLEOTIDES TOGETHER, THEN TREATING WITH OXIDIZING SOLUTION TO CONVERT H-PHOSPHONATE LINKAGES TO PHOSPHODIESTER, PHOSPHOROTHIOATE, PHOSPHORAMIDATE OR BORANOPHOSPHATE | ISIS PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | claimed |
| WO-2000047593-A1 | COMPOUNDS, PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MIXED BACKBONE OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| EP-0888543-A1 | AZATIDE PEPTIDOMIMETICS | The Scripps Research Institute (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997035199-A9 | AZATIDE PEPTIDOMIMETICS | — | 1997-12-11 | — | — | WO | claimed |
| WO-1997035199-A1 | AZATIDE PEPTIDOMIMETICS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-09-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016652-A1 | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds | PPIP5K2, NUDT1, ITPA | CA1 2336/4885CA2 2556/4885CA9 3104/4885 |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | QPCT, SSTR5, SSTR4 | CA1 781/4885CA2 2605/4885CA9 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.